KR20220045214A - 엔시펜트린(ensifentrine)을 포함하는 약학적 조성물 - Google Patents

엔시펜트린(ensifentrine)을 포함하는 약학적 조성물 Download PDF

Info

Publication number
KR20220045214A
KR20220045214A KR1020227008300A KR20227008300A KR20220045214A KR 20220045214 A KR20220045214 A KR 20220045214A KR 1020227008300 A KR1020227008300 A KR 1020227008300A KR 20227008300 A KR20227008300 A KR 20227008300A KR 20220045214 A KR20220045214 A KR 20220045214A
Authority
KR
South Korea
Prior art keywords
dry powder
pharmaceutical composition
lactose
particles
powder pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227008300A
Other languages
English (en)
Korean (ko)
Inventor
피터 라이오넬 스파르고
에드워드 제임스 프렌치
Original Assignee
베로나 파마 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베로나 파마 피엘씨 filed Critical 베로나 파마 피엘씨
Publication of KR20220045214A publication Critical patent/KR20220045214A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227008300A 2019-08-12 2020-08-12 엔시펜트린(ensifentrine)을 포함하는 약학적 조성물 Pending KR20220045214A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
GB1911517.9 2019-08-12
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine

Publications (1)

Publication Number Publication Date
KR20220045214A true KR20220045214A (ko) 2022-04-12

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008300A Pending KR20220045214A (ko) 2019-08-12 2020-08-12 엔시펜트린(ensifentrine)을 포함하는 약학적 조성물

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン(パブル) 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
ZA202201322B (en) 2024-06-26
IL290447A (en) 2022-04-01
CN114286672A (zh) 2022-04-05
BR112022002630A2 (pt) 2022-05-03
WO2021028679A1 (en) 2021-02-18
GB201911517D0 (en) 2019-09-25
WO2021028679A8 (en) 2022-02-24
CA3144713A1 (en) 2021-02-18
AU2020328223B2 (en) 2025-09-04
JP2022550664A (ja) 2022-12-05
US20220265549A1 (en) 2022-08-25
JP7678793B2 (ja) 2025-05-16
IL290447B1 (en) 2026-03-01
IL326396A (en) 2026-04-01
PH12022550322A1 (en) 2023-02-13
MY208922A (en) 2025-06-11
MX2022001724A (es) 2022-03-11
EP4013384A1 (en) 2022-06-22
AU2020328223A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
AU2020328223B2 (en) Pharmaeutical composition comprising ensifentrine
US8512753B2 (en) Micronized particles of low-dosage strength active agents for powder formulations for inhalation
DK1267866T4 (en) Treatment of respiratory diseases
EP1036562A1 (en) Soft-pellet drug and process for the preparation thereof
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
CN107205936B (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
US9987229B2 (en) Process for preparing a medicament
US20120101077A1 (en) Agglomerate formulations useful in dry powder inhalers
RU2470639C2 (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
EP1674085A1 (en) Solid lipidic particles as pharmaceutically acceptable fillers or carriers for inhalation
RU2825334C2 (ru) Фармацевтическая композиция, содержащая энсифентрин
US20080292713A1 (en) Respirable Powders
RU2422144C2 (ru) Применение солей тиотропия для лечения тяжелых форм персистирующей астмы
EA015353B1 (ru) Применение солей тиотропия для лечения персистирующей астмы средней тяжести
EP3203984B1 (en) Pharmaceutical composition containing budesonide and formoterol.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000